['non-small cell lung cancer', 'squamous non-small cell lung cancer', 'nsclc', 'small cell lung cancer', 'sclc', 'lung cancer', 'advanced lung cancer', 'metastatic lung cancer', 'stage iv lung cancer']
['lucitanib']

        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC

          -  Any of the following tumor tissue based genetic alterations: FGFR1, FGFR2, FGFR3,
             VEGFA, or PDGFRα amplification; Any FGFR1, FGFR2, or FGFR3 gene fusion; FGFR1, FGFR2,
             or FGFR3 activating mutation

          -  Availability of tumor tissue sample suitable for the central confirmation of the
             genetic alteration and exploratory analyses

          -  Eastern Cooperative Oncology Group (ECOG) of 0 or 1

          -  Measurable disease per RECIST 1.1

          -  Documented radiographic disease progression following at least one line of therapy in
             the advanced/metastatic setting

        Exclusion Criteria:

          -  Tumors that are invading a major vessel; NSCLC tumors abutting to a major vessel

          -  Uncontrolled hypertension, defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with
             optimized anti-hypertensive therapy

          -  Uncontrolled hypothyroidism defined as serum thyroid stimulating hormone (TSH) higher
             than 5 mIU/mL while receiving appropriate thyroid hormone therapy

          -  Symptomatic and/or untreated central nervous system metastases

          -  Presence of another active cancer

          -  Ongoing adverse events from surgery or prior anti-cancer therapies, including
             radiation, targeted, or cytotoxic therapies

          -  Pregnant or breastfeeding women
      